open access
Ixazomib in patients with relapsed/refractory multiple myeloma
Affiliations- Oddział Hematologiczny Centrum Onkologii Ziemi Lubelskiej, Lublin, Polska
- Zakład Hematoonkologii Doświadczalnej, Uniwersytet Medyczny w Lublinie, Lublin, Polska
- Klinika Hematologii, Onkologii i Chorób Wewnętrznych WUM, Warszawa, Polska
- Klinika Hematologii, Instytut Hematologii i Transfuzjologii, Warszawa, Polska
- Klinika Hematologii i Transplantacji Szpiku, UM w Poznaniu, Poznań, Polska
- Klinika Hematologii UM w Łodzi, Łódź, Polska
- Katedra i Klinika Hematologii i Transplantologii, Gdański Uniwersytet Medyczny, Gdańsk, Polska
open access
Abstract
Ixazomib is a new agent registered in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The drug is the first oral proteasome inhibitor. Registration data show improvement in progression-free survival time (20.6 vs 14.7 months, p=0.01) but recent analysis in Asian population also in overall survival (25.8 vs 15.8 months, HR=0.419, p=0.001) what placed with lack of ixazomib incremental toxicity may implicate clinical importance of the treatment in relapsed or refractory multiple myeloma. Oral dosing of the triplet regimen may decrease the number and duration of hospitalizations that allows for better social functioning and occupational performance, and thus impacts daily disease perception.
Abstract
Ixazomib is a new agent registered in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The drug is the first oral proteasome inhibitor. Registration data show improvement in progression-free survival time (20.6 vs 14.7 months, p=0.01) but recent analysis in Asian population also in overall survival (25.8 vs 15.8 months, HR=0.419, p=0.001) what placed with lack of ixazomib incremental toxicity may implicate clinical importance of the treatment in relapsed or refractory multiple myeloma. Oral dosing of the triplet regimen may decrease the number and duration of hospitalizations that allows for better social functioning and occupational performance, and thus impacts daily disease perception.
Keywords
Ixazomib; Multiple Myeloma; Treatment
About this articleTitle
Ixazomib in patients with relapsed/refractory multiple myeloma
Journal
Issue
Pages
160-164
Published online
2017-07-01
Page views
118
Article views/downloads
303
DOI
10.1016/j.achaem.2017.07.002
Bibliographic record
Acta Haematol Pol 2017;48(3):160-164.
Keywords
Ixazomib
Multiple Myeloma
Treatment
Authors
Krzysztof Giannopoulos
Wiesław Wiktor Jędrzejczak
Krzysztof Jamroziak
Dominik Dytfeld
Tadeusz Robak
Andrzej Hellmann